A Phase 3 interventional study of vedolizumab and Placebo in Crohn's Disease, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 114 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-21.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.
Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 16 in phase 3, and was the 3rd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Austria, Belgium and 23 more countries
Ages 18–65
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,116 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 101 across the 39 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
86 studies in Crohn Disease by Takeda: 12 open now, 14 under way, 7 of them phase 3. Of 66 finished, 37 (56%) have results posted.
Among the 86 studies in Crohn Disease by Takeda, this one is the 2nd largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2008, is one of 25 in phase 3, and was the 5th registered.
Takeda’s Crohn Disease studies by the year they started, since 2000.
5 of the studies testing vedolizumab in Crohn Disease that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 39 studies testing vedolizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 86 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
Study C13007 comprised 2 randomized, double-blind, placebo-controlled studies conducted under 1 protocol which, operationally, consisted of 2 phases.
The 6-week Induction Phase contained 2 cohorts of participants: Cohort 1 participants were randomized and treated with double-blind study drug, and Cohort 2 participants were treated with open-label vedolizumab. The second cohort was enrolled to ensure that the sample size of Induction Phase responders randomized into the Maintenance Study provided sufficient power for the Maintenance Study primary efficacy analysis. These participants did not contribute to the efficacy analyses performed for the Induction Study. Participants in both cohorts were assessed for treatment response at Week 6.
In the Maintenance Phase vedolizumab-treated participants from both Cohort 1 and Cohort 2 who demonstrated a clinical response were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks (Q4W), vedolizumab administered every 8 weeks (Q8W), or placebo. Vedolizumab-treated participants who did not demonstrate response at Week 6 continued treatment with open-label vedolizumab, administered Q4W. Participants treated with double-blind placebo in the Induction Phase continued on double-blind placebo during the Maintenance Phase, regardless of treatment response during induction. The Maintenance Phase began at Week 6 and concluded with Week 52 assessments.
After the Week 52 assessments, participants may have been eligible to enroll in Study C13008 (NCT00790933; Long-term Safety Study) to receive open-label vedolizumab treatment. Participants who withdrew early (prior to Week 52) due to sustained nonresponse, disease worsening, or the need for rescue medications may have been eligible to enroll in Study C13008. Participants who did not enroll into Study C13008 were to complete a final on-study safety assessment at Week 66 (or Final Safety visit 16 weeks after the last dose) in the Maintenance Phase of Study C13007.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents, within protocol-specified parameters:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15). In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase.
Drug: vedolizumab
In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
Other: Placebo
Vedolizumab for intravenous infusion
Also known as: Entyvio, MLN0002, MLN02, LDP-02
Placebo intravenous infusion
Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Time frame: Week 6
Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6
Enhanced clinical response is defined as a CDAI score at least 100 points lower than Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.
Time frame: Baseline and Week 6
Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52
Clinical remission is defined as a CDAI score ≤ 150. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Time frame: Week 52
Induction Phase: Change From Baseline in C-Reactive Protein (CRP) Levels at Week 6
C-reactive protein (CRP) is a protein found in the blood, the levels of which rise in response to inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age. Higher levels indicate mild inflammation (10-40 mg/L) and active inflammation (40-200 mg/L).
Time frame: Baseline and Week 6
Maintenance Phase: Percentage of Participants With Enhanced Clinical Response at Week 52
Enhanced clinical response is defined as a CDAI score at least 100 points lower than the Baseline value. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.
Time frame: Baseline and Week 52
Maintenance Phase: Percentage of Participants in Corticosteroid-free Clinical Remission at Week 52
Participants using oral corticosteroids at Baseline, who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 52 achieved corticosteroid-free clinical remission. The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free clinical remission.
Time frame: Week 52
Maintenance Phase: Percentage of Participants With Durable Clinical Remission
Durable clinical remission is defined as CDAI score ≤ 150 points at 80% or more of study visits during the Maintenance Phase, including the Week 52 visit (11 of 13 study visits). The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission
Time frame: Assessed every 4 weeks from Week 6 to Week 50, and at Week 52
Participants took part in the study at 285 investigative sites worldwide from 23 December 2008 to 08 May 2012. The Induction Phase contained 2 cohorts. The eligibility criteria for both cohorts were identical. The purpose of Cohort 2 was to provide enough responders to power the Maintenance Phase primary efficacy analysis.
| Milestone | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab Q8W | Maintenance Phase: Vedolizumab Q4W | Maintenance Phase: Non-Responders |
|---|---|---|---|---|---|---|---|
| Started | 148 | 220 | 748 | 0 | 0 | 0 | 0 |
| Treated | 148 | 220 | 747 | 0 | 0 | 0 | 0 |
| Completed | 137 | 199 | 674 | 0 | 0 | 0 | 0 |
| Not completed | 11 | 21 | 74 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 7 | 9 | 24 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 | 28 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 9 | 16 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab Q8W | Maintenance Phase: Vedolizumab Q4W | Maintenance Phase: Non-Responders |
|---|---|---|---|---|---|---|---|
| Started | 137 | 0 | 0 | 153 | 154 | 154 | 412 |
| Completed | 42 | 0 | 0 | 64 | 73 | 82 | 163 |
| Not completed | 95 | 0 | 0 | 89 | 81 | 72 | 249 |
| Withdrew: Adverse event | 7 | 0 | 0 | 15 | 12 | 9 | 38 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 2 | 3 | 4 |
| Withdrew: Lack of efficacy | 79 | 0 | 0 | 64 | 58 | 48 | 177 |
| Withdrew: Withdrawal by subject | 7 | 0 | 0 | 7 | 6 | 9 | 24 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 1 | 3 | 2 | 5 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
| percentage of participants | Placebo | DB Vedolizumab |
|---|---|---|
| Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6 | 6.8 (2.7 to 10.8) | 14.5 (9.9 to 19.2) |
Enhanced clinical response is defined as a CDAI score at least 100 points lower than Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.
| percentage of participants | Placebo | DB Vedolizumab |
|---|---|---|
| Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6 | 25.7 (18.6 to 32.7) | 31.4 (25.2 to 37.5) |
Clinical remission is defined as a CDAI score ≤ 150. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
| percentage of participants | Placebo | Vedolizumab Q8W | Vedolizumab Q4W |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52 | 21.6 (15.1 to 28.1) | 39.0 (31.3 to 46.7) | 36.4 (28.8 to 44.0) |
C-reactive protein (CRP) is a protein found in the blood, the levels of which rise in response to inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age. Higher levels indicate mild inflammation (10-40 mg/L) and active inflammation (40-200 mg/L).
| mg/L | Placebo | DB Vedolizumab |
|---|---|---|
| Induction Phase: Change From Baseline in C-Reactive Protein (CRP) Levels at Week 6 | -0.5 (-27.6 to 12.1) | -0.9 (-20.6 to 10.3) |
Enhanced clinical response is defined as a CDAI score at least 100 points lower than the Baseline value. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are: * Number of liquid or soft stools each day for 7 days; * Abdominal pain (graded from 0-3 on severity) each day for 7 days; * General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days; * Presence of complications; * Taking Lomotil or opiates for diarrhea; * Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); * Hematocrit of \< 0.47 in men and \< 0.42 in women; * Percentage deviation from standard weight. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.
| percentage of participants | Placebo | Vedolizumab Q8W | Vedolizumab Q4W |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants With Enhanced Clinical Response at Week 52 | 30.1 (22.8 to 37.3) | 43.5 (35.7 to 51.3) | 45.5 (37.6 to 53.3) |
Participants using oral corticosteroids at Baseline, who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 52 achieved corticosteroid-free clinical remission. The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free clinical remission.
| percentage of participants | Placebo | Vedolizumab Q8W | Vedolizumab Q4W |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants in Corticosteroid-free Clinical Remission at Week 52 | 15.9 (7.9 to 23.8) | 31.7 (21.6 to 41.8) | 28.8 (18.8 to 38.7) |
Durable clinical remission is defined as CDAI score ≤ 150 points at 80% or more of study visits during the Maintenance Phase, including the Week 52 visit (11 of 13 study visits). The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity. All participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission
| percentage of participants | Placebo | Vedolizumab Q8W | Vedolizumab Q4W |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants With Durable Clinical Remission | 14.4 (8.8 to 19.9) | 21.4 (14.9 to 27.9) | 16.2 (10.4 to 22.1) |
Collected over From the start of the Induction Phase until a final on-study safety assessment at Week 66 (or Final Safety visit 16 weeks after the last dose).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 23/148 (15.5%) | 96/148 (64.9%) |
| VDZ/PBO | — | 23/153 (15%) | 96/153 (62.7%) |
| VDZ/VDZ | — | 199/814 (24.4%) | 476/814 (58.5%) |
| Event | Placebo | VDZ/PBO | VDZ/VDZ |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 13/148 | 8/153 | 99/814 |
| Anal abscessInfections and infestations | 1/148 | 0/153 | 16/814 |
| Abdominal painGastrointestinal disorders | 1/148 | 2/153 | 3/814 |
| Ileal stenosisGastrointestinal disorders | 0/148 | 2/153 | 2/814 |
| Abdominal abscessInfections and infestations | 0/148 | 2/153 | 5/814 |
| Small intestinal obstructionGastrointestinal disorders | 1/148 | 1/153 | 6/814 |
| Intestinal obstructionGastrointestinal disorders | 1/148 | 0/153 | 4/814 |
| Anal fistulaGastrointestinal disorders | 1/148 | 0/153 | 1/814 |
| Anal fissureGastrointestinal disorders | 1/148 | 0/153 | 0/814 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/148 | 0/153 | 0/814 |
| Event | Placebo | VDZ/PBO | VDZ/VDZ |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 28/148 | 23/153 | 84/814 |
| HeadacheNervous system disorders | 19/148 | 28/153 | 97/814 |
| PyrexiaGeneral disorders | 17/148 | 22/153 | 102/814 |
| Abdominal painGastrointestinal disorders | 21/148 | 18/153 | 79/814 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 19/148 | 21/153 | 110/814 |
| NasopharyngitisInfections and infestations | 10/148 | 14/153 | 100/814 |
| NauseaGastrointestinal disorders | 12/148 | 18/153 | 88/814 |
| VomitingGastrointestinal disorders | 10/148 | 13/153 | 48/814 |
| DiarrhoeaGastrointestinal disorders | 5/148 | 12/153 | 31/814 |
| Upper respiratory tract infectionInfections and infestations | 11/148 | 5/153 | 54/814 |
The Induction Phase Safety Population, defined as all participants, in both Cohort 1 and Cohort 2, who received any amount of study drug in the Induction Phase (Weeks 0 to 6), according to the actual study drug received.
| Age, Continuous(years) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Mean | 38.6 ± 13.16 | 36.3 ± 11.57 | 35.6 ± 12.01 | 36.1 ± 12.12 |
| Age, Customized(participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| < 35 years | 67 | 111 | 404 | 582 |
| ≥ 35 years | 81 | 109 | 343 | 533 |
| Age, Customized(participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| < 65 years | 142 | 218 | 732 | 1092 |
| ≥ 65 years | 6 | 2 | 15 | 23 |
| Sex: Female, Male(Participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Female | 79 | 115 | 401 | 595 |
| Male | 69 | 105 | 346 | 520 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 2 | 19 | 26 |
| Not Hispanic or Latino | 139 | 214 | 712 | 1065 |
| Unknown or Not Reported | 4 | 4 | 16 | 24 |
| Race/Ethnicity, Customized(participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| White | 124 | 182 | 689 | 995 |
| Black | 3 | 3 | 17 | 23 |
| Asian | 19 | 35 | 35 | 89 |
| Other | 2 | 0 | 6 | 8 |
| Region of Enrollment(participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Australia | 5 | 10 | 30 | 45 |
| Austria | 4 | 3 | 7 | 14 |
| Belgium | 12 | 17 | 41 | 70 |
| Bulgaria | 5 | 7 | 2 | 14 |
| Canada | 22 | 12 | 103 | 137 |
| Czech Republic | 11 | 16 | 53 | 80 |
| Denmark | 0 | 2 | 8 | 10 |
| Estonia | 1 | 2 | 3 | 6 |
| France | 4 | 3 | 37 | 44 |
| Germany | 0 | 1 | 49 | 50 |
| Greece | 0 | 0 | 2 | 2 |
| Hong Kong | 2 | 0 | 0 | 2 |
| Hungary | 9 | 17 | 47 | 73 |
| Iceland | 0 | 0 | 4 | 4 |
| India | 10 | 19 | 5 | 34 |
| Ireland | 0 | 0 | 2 | 2 |
| Israel | 2 | 4 | 12 | 18 |
| Italy | 1 | 0 | 13 | 14 |
| Korea, Republic of | 3 | 12 | 11 | 26 |
| Latvia | 0 | 2 | 0 | 2 |
| Malaysia | 1 | 3 | 5 | 9 |
| Netherlands | 0 | 0 | 7 | 7 |
| New Zealand | 4 | 5 | 3 | 12 |
| Norway | 0 | 0 | 13 | 13 |
| Poland | 7 | 6 | 14 | 27 |
| Romania | 0 | 1 | 4 | 5 |
| Russian Federation | 4 | 9 | 15 | 28 |
| Serbia | 0 | 0 | 3 | 3 |
| Singapore | 1 | 0 | 0 | 1 |
| Slovakia | 3 | 5 | 10 | 18 |
| South Africa | 3 | 3 | 14 | 20 |
| Spain | 1 | 0 | 6 | 7 |
| Sweden | 0 | 1 | 8 | 9 |
| Switzerland | 0 | 1 | 9 | 10 |
| Taiwan | 0 | 0 | 3 | 3 |
| Turkey | 2 | 3 | 1 | 6 |
| Ukraine | 3 | 4 | 9 | 16 |
| United Kingdom | 0 | 0 | 6 | 6 |
| United States | 28 | 52 | 188 | 268 |
| Body Weight(kg) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Mean | 68.7 ± 18.90 | 67.1 ± 19.07 | 70.8 ± 19.56 | 69.8 ± 19.42 |
16 further baseline measures are reported on the registry.
Showing the first 100 of 114 sites across 3 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2008, a primary completion of Mar 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 2 years 4 months after primary completion. A results delay was requested in Apr 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab
Millennium Pharmaceuticals, Inc. →